Investing Profile

David Bonita

InvestorVC
General Partner at OrbiMed
orbimed.comNew York, New York
Photo of David Bonita, General Partner at OrbiMed

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
cb
OrbiMed General Partner
$1M - $75.0M
$4.0M
25
$18B
CompanyStageDateRound SizeTotal Raised
Magenta Medical
Series UnknownJul 2024$110M
Series UnknownMay 2023$55M
$160M
Rampart Bioscience
Series AOct 2023$85M
$85M
Co-investors: Dmitrij Hristodorov (Forbion)
Congruence Therapeutics
Series AMar 2023$15M
Series AFeb 2022$50M
$65M
Co-investors: Michelle Scarborough (BDC Venture Capital), Nancy Harrison (Amplitude VC)
Tricida
Post Ipo EquityNov 2021$42M
Series DNov 2017$58M
Series CJul 2016$55M
Series BMar 2015$30M
Series ASep 2014$10M
$320M
Co-investors: Scott Bluestein (Hercules Capital)
Repare Therapeutics
Series BSep 2019$83M
$150M
Co-investors: Jérôme Nycz (BDC Venture Capital)
Imara
Series BMar 2019$63M
$63M
Co-investors: Mark Chin (Arix Bioscience), Joseph Anderson (Soffinova Partners)
Third Harmonic Bio
Series AJan 2019$50M
$50M
Co-investors: Jason Rhodes (Atlas Venture), Michael Gladstone (Atlas Venture)
Sublimity Therapeutics
Series UnknownMay 2018$64M
$64M